FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1658043158> ?p ?o ?g. }

• W1658043158 endingPage "917" @default.
• W1658043158 startingPage "917" @default.
• W1658043158 abstract "Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes Jian-Qing Zhang,1 Jia-Qiang Zhang,1 Hua Liu,2 Zhi-Huan Zhao,1 Li-Zhou Fang,1 Ling Liu,1 Wei-Ping Fu,1 Jing-Kui Shu,1 Jia-Gang Feng,1 Lu-Ming Dai1 1Department of Respiratory Critical Care Medicine, 2Department of Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, Kunming, People’s Republic of China Background: The role of the antioxidant N-acetylcysteine (NAC) in the treatment of chronic obstructive pulmonary disease (COPD) has not been clarified as yet. In early studies, we found that the proportion of smokers with COPD having extremely slow/slow microsomal epoxide hydrolase (EPHX1) enzyme activity is significantly higher than that in healthy smokers. The purpose of this study was to evaluate whether different EPHX1 enzyme activity is related to differential therapeutic effects of treatment with NAC in COPD.Methods: A total of 219 patients with COPD were randomly allocated to an extremely slow/slow EPHX1 enzyme activity group (n=157) or a fast/normal EPHX1 enzyme activity group (n=62) according to their EPHX1 enzyme activity. Both groups were treated with NAC 600 mg twice daily for one year. The main study parameters, including forced expiratory volume in one second (FEV1), St George’s Respiratory Questionnaire (SGRQ), and yearly exacerbation rate, were measured at baseline and at 6-month intervals for one year.Results: Both FEV1 and SGRQ symptom scores were improved after treatment with NAC in the slow activity group when compared with the fast activity group. Further, changes in FEV1 and SGRQ symptom score in patients with mild-to-moderate COPD were more significant than those in patients with severe-to-very severe COPD. The yearly exacerbation rates were reduced in both groups, but the reduction in the slow activity group was significantly lower than in the fast activity group.Conclusion: NAC treatment in COPD patients with extremely slow/slow EPHX1 enzyme activity improves FEV1 and the SGRQ symptom score, especially in those with mild-to-moderate COPD, and polymorphism in the EPHX1 gene may have a significant role in differential responses to treatment with NAC in patients with COPD. Keywords: N-acetylcysteine, chronic obstructive pulmonary disease, microsomal epoxide hydrolase, polymorphism" @default.
• W1658043158 created "2016-06-24" @default.
• W1658043158 creator A5002656825 @default.
• W1658043158 creator A5002887909 @default.
• W1658043158 creator A5014598665 @default.
• W1658043158 creator A5032441351 @default.
• W1658043158 creator A5052759699 @default.
• W1658043158 creator A5056834769 @default.
• W1658043158 creator A5064936937 @default.
• W1658043158 creator A5071242218 @default.
• W1658043158 creator A5074542367 @default.
• W1658043158 creator A5082825376 @default.
• W1658043158 date "2015-05-01" @default.
• W1658043158 modified "2023-09-26" @default.
• W1658043158 title "Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes" @default.
• W1658043158 cites W1544705648 @default.
• W1658043158 cites W1982997810 @default.
• W1658043158 cites W1984197636 @default.
• W1658043158 cites W2001177742 @default.
• W1658043158 cites W2005672300 @default.
• W1658043158 cites W2019890818 @default.
• W1658043158 cites W2022821656 @default.
• W1658043158 cites W2028913224 @default.
• W1658043158 cites W203004440 @default.
• W1658043158 cites W2030135903 @default.
• W1658043158 cites W2040812181 @default.
• W1658043158 cites W2045749557 @default.
• W1658043158 cites W2045990744 @default.
• W1658043158 cites W2063678958 @default.
• W1658043158 cites W2063945782 @default.
• W1658043158 cites W2075430806 @default.
• W1658043158 cites W2075679076 @default.
• W1658043158 cites W2084303276 @default.
• W1658043158 cites W2089955895 @default.
• W1658043158 cites W2098115046 @default.
• W1658043158 cites W2107014409 @default.
• W1658043158 cites W2113034203 @default.
• W1658043158 cites W2116773067 @default.
• W1658043158 cites W2127951128 @default.
• W1658043158 cites W2133514480 @default.
• W1658043158 cites W2135682290 @default.
• W1658043158 cites W2146484830 @default.
• W1658043158 cites W2148850970 @default.
• W1658043158 cites W2151400308 @default.
• W1658043158 cites W2152912650 @default.
• W1658043158 cites W2158169335 @default.
• W1658043158 cites W2169113398 @default.
• W1658043158 cites W2604596332 @default.
• W1658043158 doi "https://doi.org/10.2147/copd.s79710" @default.
• W1658043158 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4437521" @default.
• W1658043158 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25999707" @default.
• W1658043158 hasPublicationYear "2015" @default.
• W1658043158 type Work @default.
• W1658043158 sameAs 1658043158 @default.
• W1658043158 citedByCount "8" @default.
• W1658043158 countsByYear W16580431582015 @default.
• W1658043158 countsByYear W16580431582017 @default.
• W1658043158 countsByYear W16580431582018 @default.
• W1658043158 countsByYear W16580431582020 @default.
• W1658043158 countsByYear W16580431582021 @default.
• W1658043158 countsByYear W16580431582023 @default.
• W1658043158 crossrefType "journal-article" @default.
• W1658043158 hasAuthorship W1658043158A5002656825 @default.
• W1658043158 hasAuthorship W1658043158A5002887909 @default.
• W1658043158 hasAuthorship W1658043158A5014598665 @default.
• W1658043158 hasAuthorship W1658043158A5032441351 @default.
• W1658043158 hasAuthorship W1658043158A5052759699 @default.
• W1658043158 hasAuthorship W1658043158A5056834769 @default.
• W1658043158 hasAuthorship W1658043158A5064936937 @default.
• W1658043158 hasAuthorship W1658043158A5071242218 @default.
• W1658043158 hasAuthorship W1658043158A5074542367 @default.
• W1658043158 hasAuthorship W1658043158A5082825376 @default.
• W1658043158 hasBestOaLocation W16580431581 @default.
• W1658043158 hasConcept C101819947 @default.
• W1658043158 hasConcept C126322002 @default.
• W1658043158 hasConcept C181199279 @default.
• W1658043158 hasConcept C185592680 @default.
• W1658043158 hasConcept C2776671928 @default.
• W1658043158 hasConcept C2776780178 @default.
• W1658043158 hasConcept C2777014857 @default.
• W1658043158 hasConcept C2777847592 @default.
• W1658043158 hasConcept C2778004101 @default.
• W1658043158 hasConcept C55493867 @default.
• W1658043158 hasConcept C71924100 @default.
• W1658043158 hasConcept C87644729 @default.
• W1658043158 hasConcept C90924648 @default.
• W1658043158 hasConceptScore W1658043158C101819947 @default.
• W1658043158 hasConceptScore W1658043158C126322002 @default.
• W1658043158 hasConceptScore W1658043158C181199279 @default.
• W1658043158 hasConceptScore W1658043158C185592680 @default.
• W1658043158 hasConceptScore W1658043158C2776671928 @default.
• W1658043158 hasConceptScore W1658043158C2776780178 @default.
• W1658043158 hasConceptScore W1658043158C2777014857 @default.
• W1658043158 hasConceptScore W1658043158C2777847592 @default.
• W1658043158 hasConceptScore W1658043158C2778004101 @default.
• W1658043158 hasConceptScore W1658043158C55493867 @default.
• W1658043158 hasConceptScore W1658043158C71924100 @default.
• W1658043158 hasConceptScore W1658043158C87644729 @default.

• next